Xavier Martínez Gómez Institutions of which they are part Predoctoral researcher Epidemiology and Public Health Vall Hebron Institut de Recerca Email Xavier Martínez Gómez Email Institutions of which they are part Predoctoral researcher Epidemiology and Public Health Vall Hebron Institut de Recerca
Research lines Vaccines The group has participated in different phase II, III and IV clinical trials focused on the study of the immunogenicity, efficacy and safety of several preventive vaccines (e.g. influenza, human papilloma virus, hepatitis B, herpes zoster, respiratory syncytial virus…). Currently, our group has expanded its line of research on the adjuvanted recombinant Herpes Zoster vaccine testing its safety and immunogenicity in pediatric immunosuppressed patients and adults =50 years of age with a prior episode of Herpes Zoster. Regarding observational studies, the group is leading a population study about the incidence of herpes zoster by risk groups (PI15/02273). Our team has also started a new line of investigation for a Respiratory Syncytial Virus vaccine in healthy pregnant women. IP: Xavier Martínez Gómez Projects ESTUDIO DEL PAPEL DE LA CENTRALIZACIÓN DEL DIAGNÓSTICO ANATOMOPATOLÓGICO Y LA APLICACIÓN DE ESTRATÉGIAS DE MEDICINA DE PRECISIÓN EN SARCOMAS IP: Cleofé Romagosa Pérez-Portabell Collaborators: Xavier Martínez Gómez, Ximena Garcia Torres Funding agency: Asociación Española Contra el Cáncer Funding: 270130 Reference: ECAEC222952DEAL Duration: 01/12/2022 - 30/11/2027 ESTUDIO DEL PAPEL DE LA CENTRALIZACIÓN DEL DIAGNÓSTICO ANATOMOPATOLÓGICO Y LA APLICACIÓN DE ESTRATÉGIAS DE MEDICINA DE PRECISIÓN EN SARCOMAS IP: Cleofé Romagosa Pérez-Portabell Collaborators: Xavier Martínez Gómez, Ximena Garcia Torres Funding agency: Asociación Española Contra el Cáncer Funding: 270130 Reference: ECAEC222952DEAL Duration: 01/12/2022 - 30/11/2027 INCIDENCIA Y HOSPITALIZACIÓN POR HERPES ZÓSTER EN CATALUÑA ENTRE 2007 Y 2017 IP: - Collaborators: Sonia Maria Uriona Tuma, Xavier Martínez Gómez Funding agency: Instituto de Salud Carlos III Funding: 24926 Reference: PI15/02273 Duration: 01/01/2016 - 30/11/2020 Development of a universal inFLUenza vaccine based on Tandem CORE technology (FLUTCORE) Grant Agreement nº 602437 IP: - Collaborators: Sonia Maria Uriona Tuma, Jose Angel Rodrigo Pendás, Susana Otero Romero, Xavier Martínez Gómez, Tomàs Pumarola Suñé Funding agency: EUROPEAN COMMISSION Funding: 81420 Reference: FLUTCORE_FP7HEALTH2013 Duration: 01/09/2013 - 31/03/2017 Pagination Current page 1 Page 2 Next page › Last page »
